$TDOC
Teladoc Health, Inc.

2021 Q4 Form 10-Q Financial Statement

#000155837021013911 Filed on November 01, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $554.2M $521.7M $288.8M
YoY Change 44.6% 80.62% 109.33%
Cost Of Revenue $175.0M $169.0M $104.7M
YoY Change 42.38% 61.41% 144.69%
Gross Profit $379.3M $352.6M $184.1M
YoY Change 45.64% 91.55% 93.43%
Gross Profit Margin 68.43% 67.6% 63.74%
Selling, General & Admin $290.9M $165.6M $83.23M
YoY Change -45.28% 99.0% 51.87%
% of Gross Profit 76.71% 46.97% 45.21%
Research & Development $72.87M $80.25M $29.96M
YoY Change -21.39% 167.88% 90.26%
% of Gross Profit 19.21% 22.76% 16.27%
Depreciation & Amortization $52.33M $51.91M $15.37M
YoY Change 57.82% 237.72% 34.59%
% of Gross Profit 13.8% 14.72% 8.35%
Operating Expenses $416.1M $245.9M $113.2M
YoY Change -37.08% 117.23% 60.44%
Operating Profit -$36.87M -$60.58M -$19.73M
YoY Change -90.81% 207.1% -1.1%
Interest Expense -$18.87M -$18.90M -$17.20M
YoY Change -9.27% 9.85% 123.38%
% of Operating Profit
Other Income/Expense, Net -$405.0K -$376.0K -$252.0K
YoY Change 49.21%
Pretax Income -$60.73M -$80.70M -$38.17M
YoY Change -87.33% 111.39% 38.09%
Income Tax -$49.74M $3.600M -$2.300M
% Of Pretax Income
Net Earnings -$10.99M -$84.34M -$35.88M
YoY Change -97.21% 135.04% 76.37%
Net Earnings / Revenue -1.98% -16.17% -12.42%
Basic Earnings Per Share -$0.53
Diluted Earnings Per Share -$68.67K -$529.0K -$429.4K
COMMON SHARES
Basic Shares Outstanding 160.1M 159.2M 81.23M
Diluted Shares Outstanding 159.4M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $896.0M $826.4M $1.190B
YoY Change 13.91% -30.58% 142.5%
Cash & Equivalents $893.5M $823.8M $1.187B
Short-Term Investments $2.537M $2.538M $3.070M
Other Short-Term Assets $5.660M $95.94M $22.00M
YoY Change -87.96% 336.1% 69.23%
Inventory $73.08M $56.94M $11.58M
Prepaid Expenses $38.26M
Receivables $169.0M $178.1M $85.80M
Other Receivables $21.17M $0.00 $0.00
Total Short-Term Assets $1.225B $1.157B $1.310B
YoY Change 15.65% -11.66% 134.79%
LONG-TERM ASSETS
Property, Plant & Equipment $27.23M $27.03M $20.36M
YoY Change -4.61% 32.72% 103.21%
Goodwill $14.50B $14.47B $1.691B
YoY Change -0.53% 755.55% 129.29%
Intangibles $1.910B $1.932B $386.6M
YoY Change -5.47% 399.78% 68.93%
Long-Term Investments
YoY Change
Other Assets $20.70M $17.89M $7.117M
YoY Change 12.78% 151.37% 11.78%
Total Long-Term Assets $16.51B $16.50B $2.139B
YoY Change -1.12% 671.04% 111.72%
TOTAL ASSETS
Total Short-Term Assets $1.225B $1.157B $1.310B
Total Long-Term Assets $16.51B $16.50B $2.139B
Total Assets $17.73B $17.65B $3.449B
YoY Change -0.12% 411.76% 119.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $47.26M $34.66M $21.41M
YoY Change 2.67% 61.88% 252.8%
Accrued Expenses $162.0M $150.9M $110.0M
YoY Change 3.85% 37.21% 103.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $14.00M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $331.0M $302.1M $200.8M
YoY Change -0.49% 50.43% 135.7%
LONG-TERM LIABILITIES
Long-Term Debt $1.235B $1.221B $963.0M
YoY Change -11.15% 26.78% 121.89%
Other Long-Term Liabilities $1.492M $1.328M $1.033M
YoY Change -7.67% 28.56% -85.56%
Total Long-Term Liabilities $1.492M $1.328M $1.033M
YoY Change -7.67% 28.56% -85.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $331.0M $302.1M $200.8M
Total Long-Term Liabilities $1.492M $1.328M $1.033M
Total Liabilities $332.5M $303.4M $201.9M
YoY Change -0.53% 50.32% 118.56%
SHAREHOLDERS EQUITY
Retained Earnings -$1.421B -$1.410B -$598.7M
YoY Change 43.2% 135.59% 22.56%
Common Stock $17.47B $17.40B $2.835B
YoY Change 3.65% 513.65% 87.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.05B $15.99B $2.231B
YoY Change
Total Liabilities & Shareholders Equity $17.73B $17.65B $3.449B
YoY Change -0.12% 411.76% 119.93%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$10.99M -$84.34M -$35.88M
YoY Change -97.21% 135.04% 76.37%
Depreciation, Depletion And Amortization $52.33M $51.91M $15.37M
YoY Change 57.82% 237.72% 34.59%
Cash From Operating Activities $83.21M $76.59M $32.20M
YoY Change -172.39% 137.86% 138.7%
INVESTING ACTIVITIES
Capital Expenditures -$22.92M -$15.10M -$9.300M
YoY Change 164.98% 62.37% 182.67%
Acquisitions
YoY Change
Other Investing Activities $2.846M -$19.61M -$146.2M
YoY Change -100.7% -86.58% -987.43%
Cash From Investing Activities -$20.07M -$34.71M -$155.5M
YoY Change -95.15% -77.67% -1277.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.625M 784.0K 420.0K
YoY Change -90.59% 86.67% -95.41%
NET CHANGE
Cash From Operating Activities 83.21M 76.59M 32.20M
Cash From Investing Activities -20.07M -34.71M -155.5M
Cash From Financing Activities 6.625M 784.0K 420.0K
Net Change In Cash 69.76M 42.67M -122.8M
YoY Change -115.22% -134.73% -442.75%
FREE CASH FLOW
Cash From Operating Activities $83.21M $76.59M $32.20M
Capital Expenditures -$22.92M -$15.10M -$9.300M
Free Cash Flow $106.1M $91.69M $41.50M
YoY Change -199.85% 120.94% 147.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150281099
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
160013751
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 tdoc Exercise Price Adjustment Ratio Closing Price Threshold Trading Days
ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays
P4D
CY2020Q4 tdoc Exercise Price Adjustment Ratio Closing Price Threshold Trading Days
ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays
P4D
dei Entity Central Index Key
EntityCentralIndexKey
0001477449
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37477
dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
635-2002
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TDOC
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
160086661
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
823828000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
733324000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2538000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
53245000
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
11277000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6412000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
178072000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
169281000
CY2021Q3 us-gaap Inventory Net
InventoryNet
56937000
CY2020Q4 us-gaap Inventory Net
InventoryNet
56498000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
95941000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47259000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
1157316000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1059607000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27027000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28551000
CY2021Q3 us-gaap Goodwill
Goodwill
14470399000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1932012000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2020864000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47935000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46647000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17890000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18357000
CY2021Q3 us-gaap Assets
Assets
17652579000
CY2020Q4 us-gaap Assets
Assets
17755281000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
34655000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
46030000
CY2021Q3 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
106252000
CY2020Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
83657000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
75891000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
94593000
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
72865000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
52356000
CY2021Q3 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
12442000
CY2020Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13453000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
42560000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
302105000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
332649000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1328000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1616000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42729000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43142000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4075000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2449000
CY2021Q3 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9561000
CY2020Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9926000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
93824000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
102103000
CY2021Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1211375000
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1379592000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
160013751
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150281099
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
160000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
150000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17399023000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
16857797000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1410469000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-992661000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1132000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18518000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15987582000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17652579000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17755281000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
521658000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
288812000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1478472000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
710641000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
169041000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
104725000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
475273000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
267887000
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
111078000
CY2020Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
52302000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
303738000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
132395000
CY2021Q3 us-gaap Selling Expense
SellingExpense
62602000
CY2020Q3 us-gaap Selling Expense
SellingExpense
23483000
us-gaap Selling Expense
SellingExpense
191251000
us-gaap Selling Expense
SellingExpense
60110000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80250000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29958000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
239017000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72244000
CY2021Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4340000
CY2020Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
25395000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
22084000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
30686000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103016000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59742000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
319404000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
162699000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
51907000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
12932000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
151907000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
32535000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
582234000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
308537000
us-gaap Costs And Expenses
CostsAndExpenses
1702674000
us-gaap Costs And Expenses
CostsAndExpenses
758556000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60576000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19725000
us-gaap Operating Income Loss
OperatingIncomeLoss
-224202000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47915000
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-850000
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1227000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-43728000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8978000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-376000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-252000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5493000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-827000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18895000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-16970000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-61493000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-38849000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-80697000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38174000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-323930000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96569000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3643000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2290000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93878000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5400000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-84340000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-35884000
us-gaap Net Income Loss
NetIncomeLoss
-417808000
us-gaap Net Income Loss
NetIncomeLoss
-91169000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-13423000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
16285000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19650000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
11610000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97763000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19599000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-437458000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79559000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
159435165
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83607902
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
155926680
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77821073
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
16001070000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5175000
CY2021Q3 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
74311000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13423000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-84340000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15987582000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22956000
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10539000
tdoc Recovered Excess Common Stock Issued For Acquisition Equity Impact
RecoveredExcessCommonStockIssuedForAcquisitionEquityImpact
40329000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
250027000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19650000
us-gaap Net Income Loss
NetIncomeLoss
-417808000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
15987582000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1294929000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7113000
CY2020Q3 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2020Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
918818000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21178000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
16285000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-35884000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2231036000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1014025000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40626000
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2473000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
918818000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
61741000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11611000
us-gaap Net Income Loss
NetIncomeLoss
-91169000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2231036000
us-gaap Net Income Loss
NetIncomeLoss
-417808000
us-gaap Net Income Loss
NetIncomeLoss
-91169000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
151907000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32535000
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
2500000
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
851000
tdoc Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment
AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment
8185000
tdoc Amortization Of Right Of Use Assets And Depreciation Of Rental Equipment
AmortizationOfRightOfUseAssetsAndDepreciationOfRentalEquipment
4643000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11353000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2320000
us-gaap Share Based Compensation
ShareBasedCompensation
240971000
us-gaap Share Based Compensation
ShareBasedCompensation
61151000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
91414000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-4096000
tdoc Accretion Of Interest
AccretionOfInterest
46843000
tdoc Accretion Of Interest
AccretionOfInterest
29459000
tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
-40631000
tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
-8978000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
5901000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6584000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4360000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1502000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3025000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-38000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-216000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19407000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16450000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34566000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5906000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2661000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2392000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3432000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-140000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11115000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
15880000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
17269000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-17352000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
9329000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
20002000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15348000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-8202000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
110782000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61425000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5611000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2872000
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
35402000
us-gaap Payments To Acquire Software
PaymentsToAcquireSoftware
14515000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
10901000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
75944000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
159663000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3150000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52906000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-177050000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22956000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40627000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
10677000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
1924000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
12053000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
4427000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
13996000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2473000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
3109000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
326000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4224000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34322000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
788700000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
92198000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
673075000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1694000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-129000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
733324000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
514353000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
823828000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1187299000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3114000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
786000
us-gaap Interest Paid
InterestPaid
7973000
us-gaap Interest Paid
InterestPaid
5612000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health” or the “Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is a global leader in providing virtual healthcare services with a focus on high quality, lower costs, and improved outcomes around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On January 4, 2021, the Company completed the acquisition of the UK-based telemedicine provider Consultant Connect Limited (“Consultant Connect”). Consultant Connect provides a platform that specializes in facilitating healthcare professional-to-professional advice and guidance in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of healthcare for consumers around the world. Livongo is pioneering a new category in healthcare, called Applied Health Signals, which is transforming the management of chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.</p>
tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
3
tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
13
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Significant estimates and assumptions by management affect areas including the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), capitalization and amortization of software development costs, the finalization of purchase accounting adjustments, Client performance guarantees, the calculation of a contingent liability in connection with an acquisition earn-out, the provision for income taxes and related deferred tax accounts, revenue recognition, contingencies, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Form 10-K”).</p>
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
521658000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
288812000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1478472000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
710641000
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
76900000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
51600000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21800000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
36800000
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
47200000
CY2020Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
18900000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
48500000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
10600000
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
48500000
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
15400000
CY2021Q3 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
20243000
CY2020Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
3468000
CY2021Q3 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
7788000
CY2020Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
2179000
CY2021Q3 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28031000
CY2020Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
5647000
CY2020Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
5647000
tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
34554000
tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
-12170000
CY2021Q3 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28031000
CY2021Q3 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
21836000
CY2020Q4 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
19591000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
501000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1431000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
34600000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
35476000
CY2021Q3 us-gaap Inventory Net
InventoryNet
56937000
CY2020Q4 us-gaap Inventory Net
InventoryNet
56498000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2239016000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
307004000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1932012000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2183399000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
162535000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2020864000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49600000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
145300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29600000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2019Q4 us-gaap Goodwill
Goodwill
746079000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
61157000
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
13812198000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-55801000
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0
tdoc Goodwill Measurement Period Adjustment Deferred Taxes
GoodwillMeasurementPeriodAdjustmentDeferredTaxes
-101536000
CY2020 tdoc Goodwill Measurement Period Adjustment Deferred Taxes
GoodwillMeasurementPeriodAdjustmentDeferredTaxes
0
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-14676000
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
22978000
CY2021Q3 us-gaap Goodwill
Goodwill
14470399000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2726000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4717000
CY2021Q3 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
16253000
CY2020Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
23167000
CY2021Q3 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
8817000
CY2020Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
7215000
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
5811000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2049000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1385000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1627000
CY2021Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
6272000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3139000
CY2021Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
5733000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2815000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13148000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11438000
CY2021Q3 tdoc Accrued Earn Out Current
AccruedEarnOutCurrent
0
CY2020Q4 tdoc Accrued Earn Out Current
AccruedEarnOutCurrent
4514000
CY2021Q3 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
4212000
CY2020Q4 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
1036000
CY2021Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
5802000
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2099000
CY2021Q3 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
6263000
CY2020Q4 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
0
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
29831000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19841000
CY2021Q3 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
106252000
CY2020Q4 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
83657000
CY2020Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
5000000
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
5901000
tdoc Equity Securities Without Readily Determinable Fair Value Sale Of Investment
EquitySecuritiesWithoutReadilyDeterminableFairValueSaleOfInvestment
10901000
CY2021Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
0
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
14594000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14872000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10927000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7233000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6028000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13997000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
67651000
CY2021Q3 tdoc Advances From Financing Companies Customer Payments Due Current
AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent
3763000
CY2021Q3 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
11718000
CY2021Q3 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
5491000
CY2021Q3 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
1031000
CY2021Q3 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
22003000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
12574026
CY2021Q3 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
3000000.0
CY2020Q3 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
10700000
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
5800000
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
11200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0070
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
71701000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20908000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
240971000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61151000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93900000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5400000

Files In Submission

Name View Source Status
0001558370-21-013911-index-headers.html Edgar Link pending
0001558370-21-013911-index.html Edgar Link pending
0001558370-21-013911.txt Edgar Link pending
0001558370-21-013911-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20210930.xsd Edgar Link pending
tdoc-20210930x10q.htm Edgar Link pending
tdoc-20210930x10q_htm.xml Edgar Link completed
tdoc-20210930xex10d1.htm Edgar Link pending
tdoc-20210930xex31d1.htm Edgar Link pending
tdoc-20210930xex31d2.htm Edgar Link pending
tdoc-20210930xex32d1.htm Edgar Link pending
tdoc-20210930xex32d2.htm Edgar Link pending
tdoc-20210930_cal.xml Edgar Link unprocessable
tdoc-20210930_def.xml Edgar Link unprocessable
tdoc-20210930_lab.xml Edgar Link unprocessable
tdoc-20210930_pre.xml Edgar Link unprocessable